Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: A modelling study

PLoS Medicine

Volumn 8, Issue 11, 2011, Pages

  Hallett, Timothy B ^a   Baeten, Jared M ^b   Heffron, Renee ^b   Barnabas, Ruanne ^b   de Bruyn, Guy ^c   Cremin, Íde ^a   Delany, Sinead ^c   Garnett, Geoffrey P ^a   Gray, Glenda ^c   Johnson, Leigh ^d   McIntyre, James ^c   Rees, Helen ^c   Celum, Connie ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONCEPTION; CONDOM; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; FEMALE; HEALTH CARE DELIVERY; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERVENTION STUDY; MALE; MATHEMATICAL MODEL; PRE EXPOSURE PROPHYLAXIS; PREGNANCY; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SOUTH AFRICA; ADOLESCENT; ATTITUDE TO HEALTH; BIOLOGICAL MODEL; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; HIGH RISK BEHAVIOR; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PATHOGENICITY; SEXUALITY; VIROLOGY;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HETEROSEXUALITY; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK-TAKING; SEXUAL PARTNERS; SOUTH AFRICA; YOUNG ADULT;

EID: 82455205791     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001123     Document Type: Article

References (70)

1. UNAIDS (2010) UNAIDS Report on the Global AIDS Epidemic. Available: http://www.unaids.org/GlobalReport/Global_report.htm. Geneva: UNAIDS.
2. Jahn A, Floyd S, Crampin AC, Mwaungulu F, Mvula H, et al. (2008) Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371: 1603-1611.
3. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
4. Hecht R, Stover J, Bollinger L, Muhib F, Case K, et al. (2010) Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet 376: 1254-1260.
5. The aids2031 Consortium (2011) AIDS: taking a long term view Upper Saddle River (New Jersey) FT Press.
6. Schwartlander B, Stover J, Hallett T, Atun R, Avila C, et al. (2011) Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 377: 2031-2041.
7. Kim SC, Becker S, Dieffenbach C, Hanewall BS, Hankins C, et al. (2010) Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 13: 24.
8. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH, (2010) Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep 7: 210-219.
9. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
10. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
11. University of Washington (2011) Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. Available: http://depts.washington.edu/astda/resources/PrEP_PressRelease-UW_13Jul2011.pdf. Accessed 17 October 2011.
12. Centers for Disease Control and Prevention (2011) CDC trial and another major study find PrEP can reduce risk of HIV infection among heterosexuals. Available: http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals.html. Accessed 17 October 2011.
13. De Cock KM, Crowley SP, Lo YR, Granich RM, Williams BG, (2009) Preventing HIV transmission with antiretrovirals. Bull World Health Organ 87: 488-488A.
14. Gostin LO, Kim SC, (2011) Ethical allocation of preexposure HIV prophylaxis. JAMA 305: 191-192.
15. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, et al. (2001) HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 286: 2560-2567.
16. Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, et al. (2007) Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 21: 501-507.
17. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
18. Attia S, Egger M, Muller M, Zwahlen M, Low N, (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397-1404.
19. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, et al. (2010) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376: 532-539.
20. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098.
21. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, et al. (2011) HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy in Rakai, Uganda. AIDS.
22. World Health Organization (2009) Antiretroviral therapy for HIV infection in adults and adolescents. Available: http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf. Accessed 17 October 2011.
23. Cohen MS, Shaw GM, McMichael AJ, Haynes BF, (2011) Acute HIV-1 infection. N Engl J Med 364: 1943-1954.
24. Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 378: 256-268.
25. Hollingsworth TD, Anderson RM, Fraser C, (2008) HIV-1 transmission, by stage of infection. J Infect Dis 198: 687-693.
26. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, et al. (2006) The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368: 531-536.
27. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2008) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
28. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
29. Family Health International (2011) FHI to initiate orderly closure of FEM-PrEP Available: http://www.fhi.org/en/Research/Projects/FEM-PrEP.htm. Accessed 17 October 2011.
30. The Microbicide Trials Network (2011) MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Available: http://www.mtnstopshiv.org/node/3619. Accessed 17 October 2011.
31. Paxton LA, Hope T, Jaffe HW, (2007) Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 370: 89-93.
32. Mishra V, Vaessen M, Bignami-Van Assche S, Hong R, (2006) Why do so many HIV-discordant couples in sub-Saharan Africa have female partners infected, not male partners [Abstract 1717]? In: Proceedings of the HIV/AIDS Implementers' Meeting; 16-19 June 2007, 2006; Kigali, Rwanda.
33. Walque DD, (2007) Sero-discordant couples in five African countries: implications for prevention strategies. Popul Dev Rev 33: 501-523.
34. Eyawo O, de Walque D, Ford N, Gakii G, Lester RT, et al. (2010) HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 10: 770-777.
35. Matovu JK, (2010) Preventing HIV transmission in married and cohabiting HIV-discordant couples in sub-Saharan Africa through combination prevention. Curr HIV Res 8: 430-440.
36. Chemaitelly H, Cremin I, Hallett TB, Abu-Raddad L, (2011) Patterns of HIV Infection among Stable Sexual Partnerships in sub-Saharan Africa. Sex Transm Infect In press.
37. Lingappa JR, Lambdin B, Bukusi EA, Ngure K, Kavuma L, et al. (2008) Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS ONE 3: e1411 doi:10.1371/journal.pone.0001411.
38. Chimbiri AM, (2007) The condom is an 'intruder' in marriage: evidence from rural Malawi. Soc Sci Med 64: 1102-1115.
39. Mugo NR, Heffron R, Donnell D, Wald A, Were EO, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS 25: 1887-1895.
40. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 362: 427-439.
41. Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret A, et al. (2009) Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS ONE 4: e5272 doi:10.1371/journal.pone.0005272.
42. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, et al. (2010) Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 375: 824-833.
43. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, et al. (2001) Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 17: 901-910.
44. Hollingsworth TD, Laeyendecker O, Shirreff G, Donnelly CA, Serwadda D, et al. (2010) HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog 6: e1000876 doi:10.1371/journal.ppat.1000876.
45. Stover J, Bollinger L, The costs of antiretroviral therapy in low and middle income countries: present commitments and future needs. Available: http://www.futureartcosts.org/questions/default.aspx?question=oneperson. Accessed 17 October 2011.
46. Over M, (2010) Sustaining and leveraging AIDS treatment. Available: http://www.cgdev.org/content/publications/detail/1424173, accessed 13-12-10. Accessed 17 October 2011.
47. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, et al. (2011) The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 25: 1753-1760.
48. South Africa National AIDS Council (2010) The South Africa antiretroviral treatment guidelines 2010. Available: http://www.doh.gov.za/docs/factsheets/guidelines/art.pdf. Accessed 19 January 2011.
49. Tengs TO, Lin TH, (2002) A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 22: 475-481.
50. Bongaarts J, Over M, (2010) Public health. Global HIV/AIDS policy in transition. Science 328: 1359-1360.
51. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, et al.eds. (2006) Disease control priorities in developing countries. Second edition New York, Washington (D.C.) Oxford University Press and The World Bank.
52. Organization WH CHOosing Interventions that are Cost Effective (WHO-CHOICE). Available: http://www.who.int/choice/en/. Accessed 17 October 2011.
53. Hastings A, (2011) Estimates of costs of delivering pre-exposure prophylaxis in South Africa. Available: https://wwwsugarsynccom/pf/D666097_644757_928835. Accessed 17 October 2011.
54. Meyer-Rath G, Brennan A, Long L, Rosen S, Pillay Y, et al. (2010) Total cost and potential cost savings of the national antiretroviral treatment (ART) programme in South Africa 2010 to 2017 [Abstract WEAE0201] In: Proceedings of the XVIII International AIDS Conference; 18-23 July 2010. Vienna, Austria.
55. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, et al. (2006) Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 20: 85-92.
56. Allen S, Meinzen-Derr J, Kautzman M, Zulu I, Trask S, et al. (2003) Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS 17: 733-740.
57. United Nations General Assembly (2011) Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS. Available: http://daccess-dds-ny.un.org/doc/UNDOC/LTD/N11/367/84/PDF/N1136784.pdf?OpenElement. Accessed 17 October 2011.
58. van de Vijver DA, Derdelinckx I, Boucher CA, (2009) Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis 199: 1310-1317.
59. Supervie V, Garcia-Lerma JG, Heneine W, Blower S, (2010) HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A 107: 12381-12386.
60. Rottingen JA, Cameron DW, Garnett GP, (2001) A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 28: 579-597.
61. Garnett GP, (2002) An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 78: 7-12.
62. Dodd PJ, Garnett GP, Hallett TB, (2010) Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 24: 729-735.
63. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B, (2010) Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS ONE 5: e13646 doi:10.1371/journal.pone.0013646.
64. Williams BG, Dye C, (2003) Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301: 1535-1537.
65. Baggaley RF, White RG, Boily MC, (2010) HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 39: 1048-1063.
66. eligibility for ART in lower income countries collaboration (2008) Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 84: i31-i36.
67. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
68. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189.
69. Mahy M, Lewden C, Brinkhof MW, Dabis F, Tassie JM, et al. (2010) Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect 86 (Suppl 2): ii28-ii34.
70. Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793.